Key result
Clinical antihyperglycemic drugs, including metformin, pioglitazone, acarbose, sitagliptin, and insulin, can improve diabetic complications by regulating the proliferation and function of endothelial progenitor cells.
Why the study?
Endothelial progenitor cells play an important role in diabetic vascular complications, and antihyperglycemics may improve diabetic complications by regulating their function.
Do antihyperglycemics improve endothelial progenitor cell function in diabetes?
Do antihyperglycemics improve endothelial progenitor cell function in diabetes?
Antihyperglycemic medications may improve diabetic vascular complications by regulating endothelial progenitor cell function in addition to lowering blood glucose.
This is the authors' abstract. We don't add key points for this paper.
Endothelial progenitor cells (EPCs) play an important role in diabetic vascular complications. A large number of studies have revealed that some clinical antihyperglycemics can improve the complications of diabetes by regulating the function of EPCs. Metformin can improve EPCs function in diabetic patients by regulating oxidative stress level or downstream signaling pathway of adenosine monophosphate activated protein kinase; Pioglitazone can delay the aging of EPCs by regulating telomerase activity; acarbose, sitagliptin and insulin can promote the proliferation, migration and adhesion of EPCs. In addition to lowering blood glucose, the effects of antihyperglycemics on EPCs may also be one of the mechanisms to improve the complications of diabetes. This article reviews the research progress on the regulation of EPC proliferation and function by antihyperglycemics.
Answers are grounded in this paper and cite their sources.
May support vascular benefits of antihyperglycemics via EPC regulation beyond glucose lowering; leaves open confirmation in prospective trials.
No takes yet. Share an insight, caveat, or question.
Han et al. (2020) conducted a review in Diabetes mellitus. Antihyperglycemics was evaluated. Clinical antihyperglycemic drugs, including metformin, pioglitazone, acarbose, sitagliptin, and insulin, can improve diabetic complications by regulating the proliferation and function of endothelial progenitor cells.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: